FDA Turns Down a Radiopharmaceutical Cancer Therapy on Manufacturing Grounds, Not on Whether It Works
The FDA rejected a neuroendocrine tumor radiopharmaceutical over manufacturing issues, not efficacy. Here is what that distinction means for patients.
Medical Daily ·